• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经胶质标志物 YKL-40 在突触核蛋白病中减少。

The glial marker YKL-40 is decreased in synucleinopathies.

机构信息

Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

出版信息

Mov Disord. 2013 Nov;28(13):1882-5. doi: 10.1002/mds.25589. Epub 2013 Jul 11.

DOI:10.1002/mds.25589
PMID:23847144
Abstract

BACKGROUND

Microglia are resident immunosurveillant cells in the central nervous system, and astrocytes are important for blood flow, plasticity, and neurotransmitter regulation. The aim of this study was to investigate whether astrocyte and microglial activation, estimated through markers in cerebrospinal fluid and serum, differed between synucleinopathies, tauopathies, and controls.

METHODS

We analyzed the glial activation markers YKL-40 and soluble CD14 in serum and cerebrospinal fluid from 37 controls, 50 patients with Parkinson's disease (PD), and 79 P+ patients (those with progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy).

RESULTS

Cerebrospinal fluid levels of YKL-40 were decreased significantly in patients who had PD compared with controls (P < 0.05), patients who had multiple system atrophy (P < 0.01), and patients who had tauopathies (P < 0.0001). In addition, cerebrospinal fluid levels of YKL-40 were significantly lower in patients who had synucleinopathies than in those who had tauopathies (P < 0.0001).

CONCLUSIONS

The decreased cerebrospinal fluid levels of YKL-40 suggest that glial activation is reduced in the brains of patients who have Parkinson's disease and synucleinopathies compared with patients who have tauopathies and controls.

摘要

背景

小胶质细胞是中枢神经系统中固有免疫监视细胞,星形胶质细胞对于血流、可塑性和神经递质调节很重要。本研究旨在探究通过脑脊液和血清标志物评估的星形胶质细胞和小胶质细胞激活在突触核蛋白病、tau 病和对照组之间是否存在差异。

方法

我们分析了 37 名对照组、50 名帕金森病(PD)患者和 79 名 P+患者(进展性核上性麻痹、皮质基底节变性和多系统萎缩)血清和脑脊液中的小胶质细胞激活标志物 YKL-40 和可溶性 CD14。

结果

与对照组相比,PD 患者的脑脊液 YKL-40 水平显著降低(P<0.05),多系统萎缩患者(P<0.01)和 tau 病患者(P<0.0001)。此外,与 tau 病患者相比,突触核蛋白病患者的脑脊液 YKL-40 水平显著降低(P<0.0001)。

结论

脑脊液 YKL-40 水平降低表明帕金森病和突触核蛋白病患者的脑内小胶质细胞激活减少,与 tau 病患者和对照组相比。

相似文献

1
The glial marker YKL-40 is decreased in synucleinopathies.神经胶质标志物 YKL-40 在突触核蛋白病中减少。
Mov Disord. 2013 Nov;28(13):1882-5. doi: 10.1002/mds.25589. Epub 2013 Jul 11.
2
Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.血清和脑脊液尿酸水平在突触核蛋白病与tau 病中的比较。
Acta Neurol Scand. 2013 Feb;127(2):e8-12. doi: 10.1111/ane.12012. Epub 2012 Sep 23.
3
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.脑脊液 α-突触核蛋白和 UCH-L1 在帕金森病和非典型帕金森综合征中的水平。
Parkinsonism Relat Disord. 2014 Apr;20(4):382-7. doi: 10.1016/j.parkreldis.2014.01.011. Epub 2014 Jan 22.
4
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.炎症标志物YKL-40在阿尔茨海默病患者的脑脊液中升高,但在帕金森病或路易体痴呆患者中则不然。
PLoS One. 2015 Aug 13;10(8):e0135458. doi: 10.1371/journal.pone.0135458. eCollection 2015.
5
Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies.皮肤活检中 Tau 蛋白的定量分析可将 Tau 病与 α-突触核蛋白病区分开来。
Brain. 2022 Aug 27;145(8):2755-2768. doi: 10.1093/brain/awac161.
6
Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.α-突触核蛋白病患者脑脊液中α-突触核蛋白水平降低:一项荟萃分析的证据
Mov Disord. 2014 Nov;29(13):1599-605. doi: 10.1002/mds.26036. Epub 2014 Sep 25.
7
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.脑内 α-突触核蛋白在多系统萎缩、帕金森病和进行性核上性麻痹中的蓄积:一项比较性研究。
Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.
8
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.YKL-40是继发进展型多发性硬化症鞘内炎症的一种脑脊液生物标志物。
J Neuroimmunol. 2016 Mar 15;292:52-7. doi: 10.1016/j.jneuroim.2016.01.013. Epub 2016 Jan 22.
9
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.一组5种脑脊液生物标志物在痴呆和/或帕金森病患者鉴别诊断中的准确性
Arch Neurol. 2012 Nov;69(11):1445-52. doi: 10.1001/archneurol.2012.1654.
10
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.帕金森病患者脑脊液中α-突触核蛋白和tau 浓度:一项队列研究。
Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.

引用本文的文献

1
Fluid biomarkers in atypical Parkinsonism: current state and future perspectives.非典型帕金森病中的体液生物标志物:现状与未来展望
J Neural Transm (Vienna). 2025 May 20. doi: 10.1007/s00702-025-02930-2.
2
Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.几丁质酶-3样蛋白1:神经炎症和退行性病变中具有多方面作用且具有治疗意义的因子。
Mol Neurodegener. 2025 Jan 18;20(1):7. doi: 10.1186/s13024-025-00801-8.
3
Biofluid Markers and Tissue Biopsies Analyses for the Prodromal and Earliest Phase of Parkinson's Disease.
生物流体标志物和组织活检分析在帕金森病的前驱期和早期阶段。
J Parkinsons Dis. 2024;14(s2):S333-S344. doi: 10.3233/JPD-240007.
4
How should we be using biomarkers in trials of disease modification in Parkinson's disease?我们应该如何在帕金森病疾病修饰治疗的临床试验中使用生物标志物?
Brain. 2023 Dec 1;146(12):4845-4869. doi: 10.1093/brain/awad265.
5
Multidimensional biomarkers for multiple system atrophy: an update and future directions.多维度生物标志物在多系统萎缩中的应用:更新与未来方向。
Transl Neurodegener. 2023 Jul 28;12(1):38. doi: 10.1186/s40035-023-00370-0.
6
Neuroinflammation and Autophagy in Parkinson's Disease-Novel Perspectives.神经炎症与帕金森病中的自噬作用:新视角。
Int J Mol Sci. 2022 Nov 30;23(23):14997. doi: 10.3390/ijms232314997.
7
Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet's disease.脑脊液神经丝轻链水平与神经 Behcet 病的疾病活动增加有关。
Turk J Med Sci. 2022 Aug;52(4):1266-1273. doi: 10.55730/1300-0144.5432. Epub 2022 Aug 10.
8
Update on CSF Biomarkers in Parkinson's Disease.帕金森病脑脊液生物标志物研究进展。
Biomolecules. 2022 Feb 18;12(2):329. doi: 10.3390/biom12020329.
9
Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis.血清 NfL 和 CHI3L1 在 ALS 和帕金森病中的诊断过程。
J Neural Transm (Vienna). 2022 Mar;129(3):301-309. doi: 10.1007/s00702-022-02470-z. Epub 2022 Feb 18.
10
Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer's Disease.阿尔茨海默病患者中YKL-40水平升高,但C反应蛋白水平未升高。
Biomedicines. 2021 Aug 27;9(9):1094. doi: 10.3390/biomedicines9091094.